2 results
Approved WMOCompleted
To demonstrate that ofatumumab is superior to teriflunomide in reducing the frequency of confirmed relapses as evaluated by the annualized relapse rate (ARR) in patients with relapsing MS
Approved WMOWill not start
Study goal is to compare the performance of the Absorb bioresorbable scaffold with a metallic drug eltuting stent in the STEMI patient.